Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observer-blinded randomized Phase 2 study of MV-CHIK chikungunya vaccine in healthy volunteers
2018-000211-25Phase 2Completed
- Sponsor
- Themis Bioscience
- Start
- Jun 2018
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MV-CHIK in Chikungunya (CHIKV), sponsored by Themis Bioscience. Primary endpoint: Primary immunogenicity endpoint. Started Jun 2018; status: completed.
02
Drugs
MV-CHIK
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on 2018-000211-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000211-25.